This post was originally published on this site
“We remain confident in Qiagen’s prospects and that the standalone value is attractive over both the short and long term,” the investor said.
Thermo Fisher’s sweetened 43 euros per share offer was “wholly inadequate” and the target’s fair value on a standalone basis was between 48 and 52 euros per share, it added.
